Cargando...
Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
Inhaled corticosteroids (ICSs) treatment combined with long-acting β(2)-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate...
Guardado en:
| Publicado en: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5654780/ https://ncbi.nlm.nih.gov/pubmed/29089754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S143656 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|